CHIR-258, a Novel, Multitargeted Tyrosine Kinase Inhibitor for the Potential Treatment of T(4;14) Multiple Myeloma

Blood - United States
doi 10.1182/blood-2004-10-3913
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Society of Hematology

Related search

In Vivo Target Modulation and Biological Activity of CHIR-258, a Multitargeted Growth Factor Receptor Kinase Inhibitor, in Colon Cancer Models

Clinical Cancer Research
Cancer ResearchOncology
2005English

Multitargeted Therapies for Multiple Myeloma

Autophagy
Cell BiologyMolecular Biology
2013English

Diagnostic Evaluation of T(4;14) in Multiple Myeloma and Evidence for Clonal Evolution

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2007English

Kinase Inhibitors as Potential Agents in the Treatment of Multiple Myeloma

Oncotarget
Oncology
2016English

Novel Drugs for the Treatment of Multiple Myeloma

Haematologica
Hematology
2010English

A Phase I Study of E7080, a Multitargeted Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Tumours

British Journal of Cancer
Cancer ResearchOncology
2012English

Targeting C-Met Receptor Tyrosine Kinase by the DNA Aptamer SL1 as a Potential Novel Therapeutic Option for Myeloma

Journal of Cellular and Molecular Medicine
Molecular MedicineCell Biology
2018English

Hsa_circ_0007841: A Novel Potential Biomarker and Drug Resistance for Multiple Myeloma

Frontiers in Oncology
Cancer ResearchOncology
2019English

Treatment of Multiple Myeloma With VLA4-targeted Nanoparticles Delivering Novel C-Myc Inhibitor Prodrug

2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy